Dialyse aktuell 2015; 19(04): 187
DOI: 10.1055/s-0035-1550395
Journal-Club
Georg Thieme Verlag KG Stuttgart · New York

Patienten mit maximaler lipidsenkender Therapie, Lipoprotein(a)-Erhöhung und kardiovas kulärer Erkrankung – Weniger kardiovaskuläre Ereignisse durch Lipoproteinapherese?

Contributor(s):
Volker Schettler
Further Information

Publication History

Publication Date:
19 May 2015 (online)

Also available at
 

Quelle: Leebmann J, Roeseler E, Julius U et al.; Pro(a)LiFe Study Group. Lipoprotein apheresis in patients with maximally tolerated lipid-lowering therapy, lipoprotein(a)-hyperlipoproteinemia, and progressive cardiovascular disease: prospective observational multicenter study. Circulation 2013; 128: 2567–2576

 

  • Literatur

  • 1 Raal FJ, Giugliano RP, Sabatine MS et al. Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials. J Am Coll Cardiol 2014; 63: 1278-1288
    CrossrefSearch in Google Scholar